Ambroxol

Small molecule

Phase 3underway

Evidence outlook · registrational

Parkinson's Disease: registrational readout pending

Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2029-02.

AMBITIOUS (NCT05287503): The trial randomized 65 participants to ambroxol or placebo with participants, care providers, investigators, and outcome assessors masked. Its primary outcomes were clinical cognitive measures. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Source is the AMBITIOUS trial preprint (SSRN, not yet peer reviewed); the quote was transcribed from indexed renderings of the abstract because the SSRN page blocks automated retrieval. The direction of the result and the companion levodopa-equivalent figure are corroborated by independent renderings.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Parkinson's Disease
Other / comorbidity
NCT03583658 · Sanofi
2018-06-30 – 2018-09-02 · Pharyngitis
What this study did
NCT00525044 · Boehringer Ingelheim
2007-08-01 – 2008-01-01 · Pharyngitis
What this study did
NCT00148499 · Boehringer Ingelheim
2005-10 – 2006-06 · Pharyngitis
What this study did
NCT00144274 · Boehringer Ingelheim
2005-04 – 2005-11 · Pharyngitis
What this study did
Phase 2/3 (2)
Parkinson's Disease
Other / comorbidity
Phase 2 (8)
Parkinson's Disease
NCT02914366 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2015-11 – 2025-12 · Parkinson's Disease Dementia
What this study did
NCT02941822 · University College, London
2016-12 – 2018-05 · Parkinson Disease
What this study did
Other / comorbidity
NCT04588285 · Helse Fonna
2021-05-04 – 2027-09-15 · Dementia With Lewy Bodies
What this study did
NCT05959850 · The Florey Institute of Neuroscience and Mental Health
2023-06-13 – 2024-12 · Amyotrophic Lateral Sclerosis
What this study did
NCT03950050 · Shaare Zedek Medical Center
2019-03-01 – 2022-12-30 · Gaucher Disease, Type 1
What this study did
NCT03415269 · Hull University Teaching Hospitals NHS Trust
2018-02-15 – 2018-04-19 · Cough
What this study did
NCT01361802 · Boehringer Ingelheim
2011-05 – 2011-08 · Pharyngitis, Pain
What this study did
Phase 1/2 (4)
Parkinson's Disease
NCT06193421 · Agyany Pharma LTD
2023-10-24 – 2026-04-30 · Parkinson Disease, GBA Gene Mutation
What this study did
Other / comorbidity
NCT04405596 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2025-01 – 2027-01 · Lewy Body Disease
What this study did
NCT01463215 · Exsar Corporation
2012-12 – 2015-08 · Type I Gaucher Disease
What this study did
NCT01713179 · Hallym University Kangnam Sacred Heart Hospital
2011-08 – 2011-10 · In the Present Study, we Investigated the Effects of Oral Ambroxol on Tear Film and Ocular Surface.
What this study did
Phase 1 (6)
Other / comorbidity
NCT01573663 · Hanmi Pharmaceutical Company Limited
2012-02 – 2012-04 · Healthy
What this study did
NCT02572609 · Boehringer Ingelheim
2011-11 – 2011-12 · Healthy
What this study did
NCT02194257 · Boehringer Ingelheim
2008-10 – 2008-12 · Healthy
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT07285369 · Agyany Pharma LTD
2025-03-01 – 2026-03-30 · Gaucher Disease, Type 3
What this study did
NCT05558878 · Ain Shams University
2022-10-01 – 2023-11 · Diabetic Neuropathy Peripheral
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Parkinson's Disease: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ambroxol: this drugPhase 3Small moleculeGBA1/glucocerebrosidasePartial signal
NCT05287503: Primary (MoCA change at 52 weeks): -0·69 ambroxol vs 0·19 placebo (n=28 per group); mean difference -1·18 (95%CI -2·63 to 0·27, p=0·053); adjusted mean difference -1·05 (95%CI -2·17 to -0·06, p=0·030), significantly worse with ambroxol. missed
Amantadine ER (Gocovri / ADS-5102)ApprovedSmall moleculeNMDA receptorReliable signal
NCT02274766: Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score (Baseline to Week 12): ADS-5102 (Amantadine HCl Extended Release) -20.7 units on a scale (Standard Error 2.2) vs Placebo -6.3 units on a scale (Standard Error 2.08)
NCT02136914: Change From Baseline in the Unified Dyskinesia Rating Scale (UDysRS) Score at Week 12 (Baseline to Week 12): ADS-5102 (340 mg) -15.9 units on a scale (Standard Error 1.62) vs Placebo -8 units on a scale (Standard Error 1.64)
Apomorphine (Apokyn)ApprovedSmall moleculeDopamine receptor (non-ergoline agonist)Weak signalNo reviewed efficacy summary in this indication
Apomorphine (Onapgo)ApprovedSmall moleculeDopamine receptor (non-ergoline agonist)Reliable signal
NCT02006121: Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population (Baseline and 12 weeks): Apomorphine Hydrochloride -2.61 Hours (95% CI -3.43 to -1.8) vs Placebo -0.75 Hours (95% CI -1.66 to 0.16)
Crexont (IPX203)ApprovedSmall moleculedopamine precursorReliable signal
NCT03670953: Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081)
Entacapone (Comtess)ApprovedSmall moleculeCOMTnot yet gradedNo reviewed efficacy summary in this indication
Foslevodopa / Foscarbidopa (Vyalev)ApprovedSmall moleculedopamine precursorReliable signal
NCT04380142: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5)
Istradefylline (Nourianz)ApprovedSmall moleculeadenosine A2APartial signal
NCT00199407: Placebo-corrected reduction in daily OFF time at endpoint: 4.6% (equivalent to 0.7 hours), P=0.03, favoring istradefylline 20mg/day over placebo.
NCT01968031: Change from baseline in daily OFF time at week 12, istradefylline 20 mg and 40 mg vs placebo: no statistically significant difference for either dose (Kyowa Hakko Kirin topline release, 13 Dec 2016; no effect estimate published in the release). missed
Levodopa (Inbrija)ApprovedSmall moleculedopamine precursorPartial signal
NCT02240030: UPDRS motor score change, predose to 30 min post-dose at week 12: CVT-301 84 mg -9.83 vs placebo -5.91; difference -3.92 (95% CI -6.84 to -1.00), p=0.0088 (LeWitt et al., Lancet Neurol 2019)
Levodopa-Carbidopa Intestinal Gel (Duopa)ApprovedSmall moleculedopamine precursorWeak signal
NCT00357994: Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): LCIG + Placebo Capsules -4.04 hours (Standard Error 0.65) vs Placebo Gel + Levodopa-Carbidopa Capsules -2.14 hours (Standard Error 0.66)
Opicapone (Ongentys)ApprovedSmall moleculeCOMTPartial signal
NCT04978597: Change in MDS-UPDRS Part III total score from baseline to Week 24: -6.5 opicapone vs -4.3 placebo; difference -2.2 (95% CI -3.9, -0.5) favoring opicapone, p=0.010
NCT01568073: Change in absolute OFF-time vs placebo: opicapone 50 mg -60.8 min (95% CI -97.2 to -24.4), p=0.0015, and non-inferior to entacapone (-26.2 min, p=0.0051); opicapone 5 mg p=0.056 and 25 mg p=0.080 vs placebo (BIPARK-1, Lancet Neurol 2016).
Parcopa
ApprovedUS marketing discontinued
Small moleculedopamine precursorPartial signal
NCT00139880: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively)
NCT00139867: Patient preference: 45% preferred Parcopa (carbidopa-levodopa orally disintegrating tablets), 35% had no preference, 20% preferred conventional carbidopa-levodopa tablets.
Pramipexole ER (Mirapex ER)ApprovedSmall moleculeDopamine D2 / D3 receptorsReliable signal
NCT00466167: UPDRS II+III score change at week 18 (adjusted mean, points): extended release -11.0, immediate release -12.8, placebo -6.1; ER vs placebo p=0.0001, IR vs placebo p<0.0001. The registry labels the unit 'percentage of change from baseline'; the publication reports score changes from baseline means of 40.0 to 41.7.
NCT00479401: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score (baseline and after 33 weeks treatment): Pramipexole Extended Release (PPX ER) -8.6 units on a scale (95% CI -9.9 to -7.2) vs Pramipexole Immediate Release (PPX IR) -8.8 units on a scale (95% CI -10.2 to -7.4) vs Placebo -3.8 units on a scale (95% CI -5.9 to -1.8)
Rasagiline (Azilect)ApprovedSmall moleculeMAO-BReliable signal
NCT01479530: Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 4, 8, 12, and 16): Azilect® -1.25 hours (Standard Error 0.16) vs Placebo -0.76 hours (Standard Error 0.16)
NCT01268891: Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 6, 10, 14, and 18): Azilect® -1.59 hours (Standard Error 0.25) vs Placebo -1.24 hours (Standard Error 0.26) missed
Rotigotine (Neupro)ApprovedSmall moleculeDopamine receptorsWeak signal
NCT01628926: UPDRS Part III change at 16 weeks, rotigotine vs placebo: -6.4 ± 1.2 (95% CI -8.7 to -4.1; p<0.001); non-inferior to ropinirole (n=420).
NCT00244387: Absolute change in off-time vs baseline: rotigotine -2.5h, pramipexole -2.8h, placebo -0.9h; vs placebo: rotigotine -1.58h (95% CI -2.27 to -0.90, p<0.0001), pramipexole -1.94h (95% CI -2.63 to -1.25, p<0.0001); responder rate (>=30% off-time reduction): rotigotine 59.7%, pramipexole 67%, placebo 35%
Rytary (IPX066)ApprovedSmall moleculedopamine precursorReliable signal
NCT00974974: Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81)
NCT00880620: Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30 (Week 30): IPX066 145mg LD -11.7 units on a scale (Standard Deviation 10.97) | IPX066 245 mg LD -12.9 units on a scale (Standard Deviation 11.42) | IPX066 390 mg LD -14.9 units on a scale (Standard Deviation 11.85) vs Placebo -0.6 units on a scale (Standard Deviation 10.37)
Safinamide (Xadago)ApprovedSmall moleculeMAO-BPartial signal
NCT03881371: Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time (At baseline and Week 16): Safinamide -1.93 Hours (Standard Deviation 2.556) vs Placebo -0.88 Hours (Standard Deviation 2.543)
NCT00605683: Primary endpoint (UPDRS III change, baseline to week 24), full ITT population (n=679): safinamide 100mg/d vs placebo borderline, P=0.073 (not met). In the pre-specified DA-monotherapy subgroup (n=666): safinamide 100mg/d significantly improved UPDRS III vs placebo, P=0.0396.
Tavapadon (Juvmo)ApprovedSmall moleculeD1/D5Reliable signal
NCT04223193: Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score (Week 26): Tavapadon -10.3 score on a scale (Standard Error 0.99) vs Placebo -1.2 score on a scale (Standard Error 0.89)
NCT04201093: Change From Baseline in the MDS-UPDRS Parts II and III Combined Score (Week 26): Tavapadon 5 mg -9.7 score on a scale (Standard Error 0.86) | Tavapadon 15 mg -10.2 score on a scale (Standard Error 0.88) vs Placebo 1.8 score on a scale (Standard Error 0.82)
Pramipexole (Sifrol/Mirapex)US approval withdrawnSmall moleculeDopamine D2/D3 receptorsPartial signal
NCT02177357: UPDRS Part II, Part III and Parts II+III combined: pramipexole significantly more effective than placebo at 15 weeks
Bemdaneprocel (MSK-DA01)Phase 3Cell therapyMidbrain dopaminergic neuronsWeak signalFeatured results are safety only in this race
BIIB122 / DNL151 (LRRK2 Inhibitor)Phase 3Small moleculeLRRK2Weak signal
NCT05348785: Phase 2b LUMA (n=648, randomized, placebo-controlled) did not slow confirmed clinical worsening; Biogen and Denali said in May 2026 that they would discontinue BIIB122/DNL151 development in idiopathic Parkinson's disease. Denali continues the Phase 2a BEACON study in LRRK2-variant carriers. missed
BuntanetapPhase 3Small moleculeAPP/tau/alpha-synuclein/TDP-43 (translation)Partial signal
NCT05357989: Primary MDS-UPDRS Part II change at month 6: 0.57 (10 mg) vs -0.10 (placebo); -0.04 (20 mg) vs -0.10 (placebo). missed
Droxidopa (Northera)Phase 3Small moleculenorepinephrine precursorPartial signalNo reviewed efficacy summary in this indication
HRG2010Phase 3Small moleculeCentral dopamine precursor (levodopa) and peripheral decarboxylase inhibitor (carbidopa/benserazide)Partial signal
NCT06596876: Primary endpoint, change from baseline in mean daily 'off' time at the end of double-blind treatment: HRG2010 shortened 'off' time compared with sustained-release carbidopa/levodopa, per Hengrui; the key secondary (good 'on' time without troublesome dyskinesia) was also improved. The company disclosed no numbers.
IncobotulinumtoxinA (Xeomin)Phase 3Protein / enzyme therapeuticacetylcholine releasenot yet graded
NCT02091739: MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 4 (Baseline and Week 4): MP: IncobotulinumtoxinA (Xeomin) (75 Units) -0.06 gram per minute (g/min) (Standard Error 0.027) | MP: IncobotulinumtoxinA (Xeomin) (100 Units) -0.13 gram per minute (g/min) (Standard Error 0.026) vs MP: Placebo -0.04 gram per minute (g/min) (Standard Error 0.033) phase 3 result · pivotal pending
Levodopa / Carbidopa (ND0612) (Onerji)Phase 3Small moleculedopamine precursorPartial signal
NCT02577523: Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5)
Piribedil (Clarium)Phase 3Small moleculeD2/D3Partial signal
NCT01007864: Primary endpoint (median reaction time, TAP battery vigilance subtest, minutes 16-30, end of treatment): piribedil 996 ms vs comparator (pramipexole/ropinirole) 954 ms; P=0.68 - no significant difference. missed
Pramipexole / Rasagiline (P2B001)Phase 3Small moleculedopamine / MAO-BReliable signal
NCT03329508: Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160). (baseline to week 12): P2B001 -7.98 score on a scale (Standard Error 0.6) vs Rasagiline Capsule -4.69 score on a scale (Standard Error 0.61) vs Pramipexole Capsule -5.32 score on a scale (Standard Error 0.61) vs Pramipexole Extended Release -8.35 score on a scale (Standard Error 0.86)
NCT01968460: Total UPDRS I, II, III Scores (Week 12): P2B001 Treatment A -5.97 units on a scale (Standard Error 0.94) | P2B001 Treatment B -5.15 units on a scale (Standard Error 0.9) vs Placebo -1.31 units on a scale (Standard Error 0.88)
PrasinezumabPhase 3Monoclonal antibodyalpha-synucleinnot yet gradedNo reviewed efficacy summary in this indication
Rotigotine (LY03003) (Jinyouping)Phase 3Small moleculeDopamine receptorsPartial signal
NCT04571164: Change from baseline in UPDRS Part II+III total score: LY03003 -11.8 vs placebo -5.6 (P<0.001)
Solengepras (CVN424)Phase 3Small moleculeGPR6Weak signalFeatured results are safety only in this race
Trigel (Lecigon)Phase 3Small moleculeCOMTPartial signalFeatured results are non-efficacy only in this race
BHV-8000Phase 2/3Small moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
VG081821ACPhase 2/3Small moleculeadenosine A2Anot yet gradedNo reviewed efficacy summary in this indication
AAV-GAD Gene TherapyPhase 2Gene therapy / editingGlutamic acid decarboxylase (GAD) gene delivered to the subthalamic nucleusWeak signal
NCT05603312: Treatment-related adverse events: 0/5 AAV-GAD low dose, 1/5 AAV-GAD high dose, and 0/4 sham surgery; treatment-related serious adverse events: 0/5, 0/5, and 0/4, respectively.
AFFITOPE PD01A / ACI-7104.056Phase 2Vaccinealpha-synucleinnot yet gradedNo reviewed efficacy summary in this indication
Ametefgene ParvecPhase 2Gene therapy / editingGDNFWeak signalFeatured results are safety only in this race
AP-472Phase 2Small moleculemGlu4not yet gradedNo reviewed efficacy summary in this indication
BezisterimPhase 2Small moleculeERK/NF-kB inflammatoryPartial signal
NCT05083260: Registered primary objectives were safety/drug-interaction; exploratory motor finding: NE3107 (bezisterim) + levodopa improved MDS-UPDRS Part 3 motor score >=3 points more than levodopa alone; roughly 6 points more in patients under age 70
Cannabidiol (Kanbis)Phase 2Small moleculecannabinoidnot yet gradedNo reviewed efficacy summary in this indication
Carbidopa / Levodopa (WD-1603)Phase 2Small moleculedopamine precursorPartial signal
NCT05036473: Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003)
CNM-Au8Phase 2Nanoparticlemitochondrial energy metabolismWeak signal
NCT03815916: NAD+/NADH ratio (primary endpoint) in the REPAIR-PD cohort (NCT03815916): +6.8% increase with CNM-Au8 (0.386 units), p=0.108 (paired t-test) — not statistically significant on its own; significance (p=0.037) was reached only in the prespecified integrated analysis combining the PD and MS (REPAIR-MS) cohorts together. missed
CPL500036Phase 2Small moleculePDE10APartial signal
NCT05297201: Change from baseline in total UDysRS score at Week 4 (LS mean difference vs placebo): 20 mg dose -12.30 units (p<0.001, Cohen's d 0.90); 40 mg dose -13.58 units (p<0.001, Cohen's d 1.00)
ENERGI-F705Phase 2Small moleculealpha-synuclein / mitochondrial ATPnot yet gradedNo reviewed efficacy summary in this indication
ENT-01Phase 2Small moleculeenteric neuronPartial signal
NCT03781791: Weekly complete spontaneous bowel movements (CSBM): rose from 0.7 to 3.2 with ENT-01 vs 0.7 to 1.2 with placebo (P < 0.001), n=150 (Camilleri et al., Ann Intern Med 2022).
Exenatide (PT320)Phase 2PeptideGLP-1 receptorPartial signal
NCT04269642: Primary endpoint, mean change in MDS-UPDRS part 3 score: no statistical significance between test group 1 and the placebo group (p=0.7355); in test group 2 motor symptoms improved but again without statistical significance versus placebo (p=0.5042). missed
ExidavnemabPhase 2Monoclonal antibodyalpha-synucleinWeak signalNo reviewed efficacy summary in this indication
GlovadalenPhase 2Small moleculeD1 receptorPartial signal
NCT06055985: Change from baseline to Day 70 in average hours/day of OFF time (ATLANTIS trial, n=207, 1:1:1 low-dose/high-dose/placebo): low-dose UCB0022 (glovadalen) reduced OFF time by 0.8 hours/day vs placebo; high-dose reduced it by 0.45 hours/day vs placebo
GT-02287Phase 2Small moleculeGBA1/glucocerebrosidasenot yet gradedNo reviewed efficacy summary in this indication
HBI-002Phase 2Small moleculeCarbon monoxide (CO)-based gas therapeutic; oral liquid CO formulationnot yet gradedNo reviewed efficacy summary in this indication
KM-819Phase 2Small moleculeFAF1Weak signalFeatured results are safety only in this race
Lenrispodun (ITI-214)Phase 2Small moleculePDE1Partial signalNo reviewed efficacy summary in this indication
Lu AF28996Phase 2Small moleculeD1/D2Weak signalNo reviewed efficacy summary in this indication
Matsupexole (KDT-3594)Phase 2Small moleculeD2/D3Partial signalNo reviewed efficacy summary in this indication
Mesdopetam (IRL790)Phase 2Small moleculeD3Partial signal
NCT04435431: Primary endpoint, change in daily hours of good ON-time (ON-time without troublesome dyskinesia), mesdopetam vs placebo at 12 weeks: not statistically significant. Secondary endpoint UDysRS (ON-phase dyskinesia) improved at 7.5 mg bid (nominal p = 0.026). missed
NCT03368170: Unified Dyskinesia Rating Scale (UDysRS) (Baseline and 4 weeks): Mesdopetam -4.2 score on a scale (95% CI -7.3 to -1) vs Placebo -7 score on a scale (95% CI -10.3 to -3.8) missed
MT101-5Phase 2Small molecule—Partial signalNo reviewed efficacy summary in this indication
NEU-411Phase 2Small moleculeLRRK2not yet gradedNo reviewed efficacy summary in this indication
NouvNeu001Phase 2Cell therapydopaminergic neuron replacementnot yet gradedNo reviewed efficacy summary in this indication
ParunoflastPhase 2Small moleculeNLRP3 inflammasome, NLRP3Weak signalFeatured results are safety only in this race
Pirepemat (IRL752)Phase 2Small molecule5-HT/norepinephrinePartial signal
NCT05258071: Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment. (Baseline to end of full dose treatment (up to Day 84).): Pirepemat 300 mg 76.9 % of baseline fall rate (Standard Deviation 72.05) | Pirepemat 600 mg 64.5 % of baseline fall rate (Standard Deviation 49.18) vs Placebo 68.9 % of baseline fall rate (Standard Deviation 90.22) missed
Pramipexole ER / Aprepitant (CTC-413)Phase 2CombinationDopamine D2/D3 receptors (pramipexole component) and Neurokinin-1 (NK1) receptor (aprepitant component)Weak signalNo reviewed efficacy summary in this indication
Risvodetinib (IkT-148009)Phase 2Small moleculec-AblWeak signalFeatured results are safety only in this race
PR001 (LY3884961)Phase 1/2Gene therapy / editingGBA1/glucocerebrosidasenot yet gradedNo reviewed efficacy summary in this indication
VGN-R08bPhase 1/2Gene therapy / editingGBA1/glucocerebrosidasenot yet gradedNo reviewed efficacy summary in this indication
CAP-003
—(overall)
Gene therapy / editingGBA1/glucocerebrosidasenot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 64 furthest-along competitors are listed; 61 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ambroxol to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 2Dementia With Lewy BodiesRecruiting
Est. primary completion 2027-09-15 · NCT04588285 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 3Parkinson's DiseaseRecruiting
Est. primary completion 2029-02 · NCT05778617 · CT.gov ↗
What to watch

See the full readout calendar ↗